Tissue & Cell Technologies
Tissue & Cell Technologies offers the proprietary ADIPOSET® cryopreservation platform for long-term storage and retrieval of large-volume human adipose tissue, serving NHS hospitals, private plastic surgery clinics, and patients seeking fat banking across the UK, US, and planned Europe and Middle East markets.
- Company typePrivate
- Founded2011
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Tissue & Cell Technologies does
Tissue & Cell Technologies (T&CT) is a privately held UK medtech company founded in 2011 and headquartered at the St John's Innovation Centre in Cambridge. The company develops and commercializes the proprietary ADIPOSET® cryopreservation platform, which it describes as the only approved process for the long-term storage of large volumes (20ml to 2000ml) of human adipose tissue, maintaining 75-85% cell viability over storage periods demonstrated beyond 8 years. T&CT operates under a Human Tissue Authority (HTA) tissue establishment license and a GMP-compliant Quality Management System, and has been used in 1,300+ patient procedures over a commercial track record of more than 10 years.
The company's product portfolio centers on ADIPOSET® and its derivatives — Regenerys® XL for large-volume procedures such as BBL and breast reconstruction, Regenerys® mL for smaller aesthetic procedures, and LipoStor® for long-term personal fat banking or "bio-insurance." Adjacent products include MySkin™ and CryoSkin™ for burn and wound care. T&CT serves NHS hospital trusts (Royal Free London, Addenbrooke's, Nottingham, Guy's and St Thomas', Oxford, North Tees and Hartlepool), private plastic surgery clinics in the United States, and individual patients across the UK, US, and planned markets in Europe and the Middle East. It maintains research and clinical collaborations with the Wellcome MRC Cambridge Stem Cell Institute, the Universities of Sheffield, Bradford, and Verona, and Clinic San Francesco Verona.
T&CT generates revenue through a hybrid model combining one-time processing and product kit fees (Regenerys line), professional services to NHS trusts for fat storage integrated into breast reconstruction workflows, and recurring quarterly storage subscriptions under LipoStor® with separate retrieval fees after a minimum five-year holding period. Go-to-market blends direct enterprise sales to NHS hospitals, a physician locator network spanning multiple US states, and patient-facing portals for direct storage enquiries. No public funding rounds, institutional venture capital, or revenue figures have been disclosed in the available materials.
Tissue & Cell Technologies firmographics
Firmographics- Name
- Tissue & Cell Technologies
- Legal name
- T&CT Ltd
- Website
- https://tissueandcell.tech
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tissue & Cell Technologies offers the proprietary ADIPOSET® cryopreservation platform for long-term storage and retrieval of large-volume human adipose tissue, serving NHS hospitals, private plastic surgery clinics, and patients seeking fat banking across the UK, US, and planned Europe and Middle East markets.
- Ownership category
- akta.pro rank
Tissue & Cell Technologies industry classification
Industry- Product category
- Cryopreservation and Tissue Banking Services
- NAICS
- Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)
- akta.pro secondary industries
- Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where Tissue & Cell Technologies is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices4 records
Markets served
Tissue & Cell Technologies business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Fat Banking Services: Processing and long-term storage of patient adipose tissue. Services include tissue collection, cryopreservation, and retrieval. LipoStor option offers one up-front processing charge with quarterly storage subscription.
- Product Sales - Regenerys XL: All-in-one solution for large volume procedures (BBL, breast reconstruction). Complete kit with transit box, paperwork, bags, and connectors.
- Product Sales - Regenerys mL: All-in-one solution for smaller volumes (breast augmentation, facial fillers).
- LipoStor Bio Insurance: Long-term personalized stem cell bio-insurance service with quarterly subscription model for storage after initial processing fee.
- Professional Services - NHS Contracts: Fat storage services provided to NHS hospitals including Royal Free London and Addenbrooke's Hospital for breast reconstruction workflows.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Hybrid | Quarterly | LipoStor long-term fat storage up to 250ml |
| Other | Other | Regenerys XL large volume solution |
| Other | Other | Regenerys mL smaller volume solution |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Tissue & Cell Technologies product offering
Product offeringCore offering
Tissue & Cell Technologies (T&CT) provides long-term cryopreservation services for human adipose tissue using its proprietary ADIPOSET® System, enabling hospitals, surgeons, and patients to store fat and regenerative cells (20ml–2000ml volumes) at -196°C with 75–85% post-thaw cell viability over periods from 1 month to 8+ years. Around this core platform the company sells Regenerys® XL and Regenerys® mL procedure kits, offers LipoStor® bio-insurance storage subscriptions, and distributes MySkin™/CryoSkin™ autologous skin grafting products for burns and wounds.
Product overview
Tissue & Cell Technologies offers a comprehensive portfolio of fat and tissue banking products built around the ADIPOSET® System platform. The core ADIPOSET® technology enables long-term cryo-storage of large volumes of human adipose tissue while maintaining 75-85% cell viability. This platform supports multiple product lines: Regenerys® XL for large-volume procedures (BBL, breast reconstruction), Regenerys mL® for smaller-volume aesthetic procedures (facial fillers, breast augmentation), and LipoStor® for long-term personal bio-insurance storage. Additionally, the company has developed skin grafting products including MySkin™ and CryoSkin™ for burns and wound care applications.
Differentiator
Problem solved
Functional benefit
Brands
- ADIPOSET® System: Proprietary system for long-term cryo-storage of large volumes of human adipose tissue, maintaining 75-85% cell viability
- Regenerys XL
- Regenerys mL
- LipoStor
- MySkin
- CryoSkin
Products and services
- ADIPOSET® System Proprietary cryopreservation system that enables long-term storage of large volumes (20ml to 2000ml) of human adipose tissue at -196°C in liquid nitrogen while maintaining 75–85% cell viability and tissue architecture, delivered to NHS hospitals, private clinics and physician networks.
- Regenerys® XL All-in-one kit solution for large-volume fat grafting procedures such as Brazilian Butt Lift (BBL) and breast reconstruction, including transit box, paperwork, bags and connectors, sold to plastic surgeons and clinics.
- Regenerys® mL All-in-one kit solution for smaller-volume fat grafting procedures such as breast augmentation and facial fillers, sold to plastic surgeons and clinics as an all-natural alternative to synthetic fillers.
- LipoStor® Long-term personalized bio-insurance fat storage service allowing patients (via registered physicians) to bank up to 250ml of adipose tissue with a one-off up-front processing charge and quarterly storage subscription, plus separate thaw fees after a five-year minimum.
- MySkin™ Autologous spray skin product for extreme burns and wounds, culturing cells from a small skin sample and delivering them for spray application, used in NHS burns centres since 2009 prior to integration into the T&CT portfolio.
- CryoSkin™ Advanced proprietary skin grafting product for burns and wounds, positioned alongside MySkin™ for the Middle East market launch.
Quantifiable outcome
- 75-85% cell viability maintained after thawing
- +4 more outcomes
Companies that use Tissue & Cell Technologies
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
Tissue & Cell Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Tissue & Cell Technologies partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, major and minor.
- University of SheffieldcoreOver 15 years of collaborative research in tissue engineering and cryopreservation. University provided postgraduate tissue engineering research foundation for ADIPOSET technology development. Dr. David Haddow completed postgraduate tissue engineering research at Sheffield.
- Wellcome MRC Cambridge Stem Cell InstitutemajorBroad-ranging collaboration including heart muscle patch research for regenerative medicine applications.
- Nottingham University Hospital NHS TrustcoreMulti-center study lead (Mr. Douglas Macmillan) for cost-effectiveness and PROMs evaluation of ADIPOSET versus standard care in breast reconstruction. Ongoing collaboration on clinical evidence generation.
- Clinica San Francesco, Verona & University of Verona, ItalymajorLead investigators Dr. Gino Rigotti and Professor Andrea Sbarbati studying biological mechanisms in stored fat-enabled Rigottomy procedures (2021/2022).
- University of BradfordmajorCollaboration with Dr. Julie Thornton on developing first standardized adipose-derived regenerative therapies for personalized medicine (2020/2021).
- Royal Free London NHS Foundation TrustcoreNewest NHS customer (April 2024). Mr. Ash Mosahebi and team integrating fat storage into breast reconstruction workflow. Collaborations planned on studies and research.
- Addenbrooke's Hospital, CambridgecoreMajor NHS client (March 2024). Mr. Amit Agrawal and team bringing fat storage to breast reconstruction. Plans for collaboration on studies and research.
- Guys and St Thomas's NHS Foundation TrustmajorStudy lead Ms. Pari-Naz Mohana investigating cryopreserved adipose tissue outcomes in breast reconstruction (2020-).
- Oxford University Hospitals NHS TrustmajorMr. Peter Kalu leading study on cryopreserved autologous tissue for revision plastic surgery in breast surgery (2020-).
- North Tees and Hartlepool NHS Foundation TrustminorPilot study on autologous adipose tissue banking in breast reconstruction following cancer (2017 concluded).
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Tissue & Cell Technologies competitors and assessment
Company assessmentDirect peers
- Cryoport Systems: Cryoport offers temperature-controlled logistics and cryogenic storage for life sciences, comparable to T&CT's LN2-based tissue storage and cold-chain transport operations for clinical materials.
- MiMedx: MiMedx develops and commercializes regenerative wound care and soft-tissue products derived from human tissue, directly comparable to T&CT's MySkin and CryoSkin wound-care product lines and adipose-based regenerative approach.
- Organogenesis: Organogenesis is a regenerative medicine company selling skin and wound-care biologics, overlapping with T&CT's skin substitute and autologous tissue products for burns and reconstructive surgery.
- BioLife Solutions: BioLife Solutions provides biopreservation media and cold-chain tools for cell and gene therapies, directly overlapping with T&CT's cryopreservation and cold-chain storage business for biologics and cell-based products.
Emerging players
- Establishment Labs: Establishment Labs develops breast implant and aesthetic surgery technologies, adjacent to T&CT's breast reconstruction and augmentation use cases served via Regenerys XL and the ADIPOSET platform.
- Vericel: Vericel develops autologous cell therapies for cartilage repair and burn treatment, partially comparable to T&CT's autologous tissue and cell-based therapeutic pipeline in reconstructive and regenerative indications.
- GC Aesthetics: GC Aesthetics is a global aesthetics company focused on breast implants and related products, comparable to T&CT's aesthetic surgery segment in breast augmentation and reconstruction workflows.
Broad incumbents
- Stemcell Technologies: Stemcell Technologies is a broad life science tools provider for cell culture, cryopreservation, and regenerative medicine workflows, overlapping with T&CT's core cryopreservation capabilities but serving a much wider research customer base.
- Integra LifeSciences: Integra LifeSciences provides regenerative tissue technologies and wound care solutions, comparable to T&CT's skin substitute and dermal regeneration products but operating at much larger scale across multiple specialties.
- Smith & Nephew (Advanced Wound Management): Smith & Nephew is a large diversified wound-care incumbent whose advanced wound biologics overlap with T&CT's MySkin and CryoSkin skin regeneration products, though Smith & Nephew serves a far broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks1 record
Key highlights7 records
Customer concentration
Tissue & Cell Technologies social profiles
Digital presenceTissue & Cell Technologies compliance and trust
Trust signalCompliance2 records
Tissue & Cell Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tissue & Cell Technologies leadership team
Management profileNumber of profiles
Profiles7 records
Tissue & Cell Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tissue & Cell Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tissue & Cell Technologies
What does Tissue & Cell Technologies do?
Tissue & Cell Technologies (T&CT) provides long-term cryopreservation services for human adipose tissue using its proprietary ADIPOSET® System, enabling hospitals, surgeons, and patients to store fat and regenerative cells (20ml–2000ml volumes) at -196°C with 75–85% post-thaw cell viability over periods from 1 month to 8+ years. Around this core platform the company sells Regenerys® XL and Regenerys® mL procedure kits, offers LipoStor® bio-insurance storage subscriptions, and distributes MySkin™/CryoSkin™ autologous skin grafting products for burns and wounds.
Is Tissue & Cell Technologies a public or private company?
Tissue & Cell Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Tissue & Cell Technologies founded?
Tissue & Cell Technologies was founded in 2011. It employs 11 to 50 people.
Where is Tissue & Cell Technologies based?
Tissue & Cell Technologies is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Tissue & Cell Technologies make money?
Five revenue lines are on record. Fat Banking Services are the primary driver. The others are product Sales - Regenerys XL, product Sales - Regenerys mL, lipoStor Bio Insurance and professional Services - NHS Contracts.
Who are Tissue & Cell Technologies's main competitors?
Direct peers on record are Cryoport Systems, MiMedx, Organogenesis and BioLife Solutions. Emerging players are Establishment Labs, Vericel and GC Aesthetics. Broad incumbents are Stemcell Technologies, Integra LifeSciences and Smith & Nephew (Advanced Wound Management).
Does Tissue & Cell Technologies have an API?
No public API is recorded for Tissue & Cell Technologies.
What industry is Tissue & Cell Technologies in?
Tissue & Cell Technologies's product category is Cryopreservation and Tissue Banking Services. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 621991 and its SIC code is 2836.